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p-glycoprotein (P-gp) largely influences the pharmacokinetics (PK) and toxicities of xenobiotics in a 
patient-specific manner so that personalized drug scheduling may lead to significant patient’s benefit. 
this systems pharmacology study investigated P-gp activity in mice according to organ, sex, feeding 
status, and circadian time. Sex-specific circadian changes were found in P-gp ileum mRNA and protein 
levels, circadian amplitudes being larger in females as compared to males. plasma, ileum and liver 
concentrations of talinolol, a pure P-gp substrate, significantly differed according to sex, feeding 
and circadian timing. A physiologically-based pK model was designed to recapitulate these datasets. 
estimated mesors (rhythm-adjusted mean) of ileum and hepatic p-gp activity were higher in males as 
compared to females. Circadian amplitudes were consistently higher in females and circadian maxima 
varied by up to 10 h with respect to sex. Fasting increased P-gp activity mesor and dampened its rhythm. 
Ex-vivo bioluminescence recordings of ileum mucosae from transgenic mice revealed endogenous 
circadian rhythms of p-gp protein expression with a shorter period, larger amplitude, and phase delay 
in females as compared to males. Importantly, this study provided model structure and parameter 
estimates to refine PK models of any P-gp substrate to account for sex, feeding and circadian rhythms.
Permeability-glycoprotein (P-gp), also known as Multi-Drug Resistance 1 (MDR1) or ATP Binding Cassette B1 
(ABCB1), is an important member of the ATP Binding Cassette (ABC) transporter family that plays a major 
role in pumping many endogenous substances and xenobiotics out of cells. In particular, P-gp function is crit-
ical for drug detoxification both in healthy and diseased tissues1. Differences in P-gp expression between and 
within subjects may be responsible for the large variabilities observed in drug accumulation in healthy tissues 
and associated drug toxicities. As drug tolerability remains a clinical issue, especially in oncology with estimated 
treatment-related mortality of up to 3%2, a better understanding of P-gp activity dynamics in specific organs of 
individual patients would help optimizing drug administration and reducing severe side effects. This may in turn 
circumvent pharmacologic resistance, a frequent cause of cancer treatment failures3.
According to extensive experimental and clinical investigations, both P-gp activity and the tolerability of 
P-gp-transported agents can largely vary as a function of sex, genetic polymorphisms, feeding patterns and circa-
dian time4–9. Thus, optimizing P-gp substrates administration represents a multi-factorial challenge which, in our 
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views, could be best addressed using systems pharmacology. Such inter-disciplinary approaches offer to develop 
quantitative frameworks mechanistically representing the drug pharmacokinetics-pharmacodynamics (PK-PD) 
at the molecular scale. It then integrates multi-type datasets to generate testable predictions in experimental mod-
els and in patients, following scaling up to fit human situations10.
Thus, experimental approaches alone have not been able to draw any clear conclusion regarding a possible 
sex-dependence in P-gp expression5,6,11. Positive studies found an increased P-gp expression in the liver of men 
compared to women6,12. Sex-related variations were also reported for both tolerability and therapeutic response 
of anticancer drugs in laboratory animals and in cancer patients6,9. Worse toxicities and better response rates and 
survival have been consistently reported for women as compared to men on cancer chemotherapy for the vast 
majority of cancer types13,14. This may be explained in part by increased drug accumulation resulting from low 
P-gp expression in tissues of females as compared to males. Of note, none of these studies specified the circadian 
time of P-gp determination or the feeding patterns.
P-gp, like many transporters, is regulated by nuclear receptors, such as C-androstane receptors, that are in 
turn regulated by circadian clock-controlled transcription factors15. The mammalian circadian timing system 
(CTS) involves a hierarchical network of molecular clocks that reside within each cell and are coordinated by the 
suprachiasmatic nuclei (SCN), a hypothalamic pacemaker, that can be entrained to exactly 24 h by external cues. 
The CTS rhythmically regulates most cellular functions involved in drug absorption, distribution, metabolism, 
elimination and toxicity (ADMET). Interestingly, the mRNA expression of Abcb1 which encodes for the main 
constituent of P-gp, was rhythmic in synchronized cultures of human colorectal cancer Caco-2 cells at confluence. 
Turning off the clock by silencing the core clock gene BMAL1 ablated this circadian oscillation16. The expression 
of Abcb1a/b, the two rodent homologues of the human Abcb1 was also rhythmic in the liver and intestine of 
male rats and mice17–19. Further, the circadian variations of Abcb1a/b mRNA expressions were suppressed in the 
ileum of mice harboring a constitutive mutation of Clock20. P-gp activity also displayed a circadian pattern in the 
intestine of male rats and male monkeys21,22.
The circadian regulation of P-gp could indeed represent an important chronopharmacology mechanism to 
be considered specifically in order to optimize the delivery of medications through so-called chronotherapy 
schedules. Thus, the tolerability of anticancer P-gp substrates can vary by up to several-fold according to their 
time of administration within the 24-h span23. For instance, single agent docetaxel or doxorubicin, two P-gp 
substrates, were significantly best tolerated by mice following dosing near the middle of the rest span and most 
toxic 12 h later, during the nocturnal activity phase24. The cellular PK-PD of irinotecan, an anticancer agent whose 
efflux is mediated by P-gp among other ABC transporters, varied significantly according to circadian timing 
in clock-proficient but not in clock-deficient Caco-2 cells16. Furthermore, the dosing time dependency in PK 
(chronoPK) and toxicity (chronotoxicity) of irinotecan significantly varied according to sex and genetic back-
ground in mice25–27. Similarly, large sex-related differences were found in mice regarding the chronotoxicity of 
theprubicin, another P-gp substrate anticancer drug28–30. Randomized clinical trials and meta-analyses in cancer 
patients further suggested that the circadian timing associated with least toxicity and/or efficacy of cancer chemo-
therapy could largely differ between men and women9,23.
Feeding patterns also seemed to influence ABC transporter expressions and activities, thus altering the ther-
apeutic index of many xenobiotics, including anticancer agents31. Indeed, 12 to 24 h fasting increased the hepatic 
expression of P-gp and other ABC transporters through Pparα pathway activation in male mice8, or through Nrf2 
up-regulation both in male mice and in Huh-7 human male liver cancer cell line7. Hence, proper feeding patterns 
might up-regulate ABC transporters in healthy tissues, thus reducing chemotherapy side effects31. In addition, 
feeding status influenced the chronobiology of the gastro-intestinal tract of mammals, and in particular the cir-
cadian expression of hepatic and intestinal transporters32–35. Thus, restricted feeding for a few hours over several 
consecutive days phase shifted the intestinal transport rhythms in such a way that transporter function increased 
before the programmed feeding36. Similarly, feeding restricted to the light phase shifted the rhythm of Abcb1a 
mRNA expression in the male rat intestine37.
Here, we aimed to provide a physiologically-based modeling framework encompassing sex, feeding patterns 
and circadian rhythms, for the quantitative study of the pharmacology of P-gp drug substrates, towards the opti-
mization of their dosing time and schedule.
Results
Sex-specific circadian changes in P-gp expression in ileum. Statistically significant circadian rhythms 
were found for both Abcb1a and Abcb1b mRNA expressions in the ileum mucosa, yet with differences according 
to sex (ZT effect from ANOVA on both sexes, p = 0.002 for Abcb1a; p < 0.0001 for Abcb1b; Fig. 1A,B). Highest 
expressions of both mRNA levels were found from ZT9 to ZT12 in female mice, i.e. near the end of the light span, 
and from ZT12 to ZT18 in male mice, i.e. during the beginning of the dark span. ANOVA test of sex effect was 
not statistically significant either for Abcb1a or for Abcb1b. However, according to cosinor analysis, the 24-h mean 
of Abcb1a expression was higher in females as compared to males whereas those of Abcb1b were similar in both 
sexes (Table S1). A phase advance of approximately 1.5 h was found for both mRNA rhythms in females compared 
to males. The relative amplitudes of Abcb1a was 62% of the mesor in females as compared to 37% in males. Similar 
results were found for the relative amplitude of Abcb1b: 67% and 47% respectively.
Regarding P-gp protein expression, a 24 h-rhythm with a maximum at ZT15 was found for female mice 
whereas male mice displayed damped circadian variations. ANOVA identified statistically significant effects of 
ZT, sex and ZT*sex interactions (p < 0.0001 for all). A 24 h-rhythm and significant 12 h and 8 h harmonics were 
found with cosinor analysis in females whereas males displayed a rhythm of period 12 h with an 8 h-harmonic 
(Fig. 1C). Similarly, to what was found for the mRNA levels, i) the 24 h-means and amplitudes were higher in 
females as compared to males, ii) a phase advance of approximately 2 h was observed in the dominant rhythm of 
females as compared to males. P-gp protein expression was mainly observed in the plasma membrane of mucosa 
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Figure 1. Sex-specific P-gp expression in the Ileum mucosa. (A–C) Circadian patterns of Abcb1a (A) and 
Abcb1b (B) mRNA expression, and whole P-gp protein (C) in female (red) and male (blue) ad libitum fed mice. 
Each data point is the average (±SEM) of 5 animals. Solid lines are the best-fit cosinor (Table S1). Regarding 
mRNAs, a 24 h-rhythm was found by the cosinor analysis for Abcb1a (male, p = 0.042; female, p = 0.0017), 
and Abcb1b (male, p = 0.02; female, p < 0.001). For P-gp protein, a 24 h-rhythm with significant 12 h- and 
8 h-harmonics (p < 0.001 for all harmonics) was found in females and a 12 h-rhythm with a 8 h-harmonic was 
found in males (p = 0.002 and p = 0.001, respectively). (D–G) Confocal immunohistochemistry imaging of 
ileum P-gp protein expression at ZTs of minimum and maximum expression that were in female mice at ZT3 
(D) and ZT15 (E), and in male mice at ZT12 (F) and ZT18 (G). Pictures represent merged images showing cell 
nuclei (blue), P-gp (green), β-catenin (red) and co-localization of P-gp and β-catenin (yellow). The scale bar 
represents 20 µm.
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cells, as indicated by its co-localization with β-catenin, a reference plasma membrane marker (Fig. 1D,E, Figs S1, 
S2 in SI). β-catenin was used as a co-localization marker, and its changes in staining intensities according to sex 
and/or timing were not examined.
Sex-specific circadian changes in P-gp expression in colon. The 24-h means of Abcb1a and Abcb1b 
mRNA expressions were significantly higher in males as compared to females (ANOVA testing sex effect, 
p < 0.0001), yet they were arrhythmic in both sexes (non-significant ZT effect with ANOVA and non-significant 
24 h or 12 h rhythm detection with cosinor; Fig. 2A,B, Table S2 in SI). Regarding P-gp protein, 24 h-mean val-
ues were similar in males and in females (non-significant sex effect from ANOVA). No rhythm of P-gp pro-
tein expression in the colon was found for males (non-significant ZT effect from ANOVA and no rhythm with 
cosinor; Fig. 2C–G). However, a significant 12 h-rhythm with a relative amplitude of 22% of the mesor was found 
in females. The sex*ZT interaction was statistically significant (ANOVA, p = 0.04).
talinolol pK analysis according to sex, feeding conditions and circadian timing. Talinolol was 
used to investigate P-gp activity at whole organism level in mice of both sexes, either ad libitum fed or fasted, 
following dosing at one of two circadian times (Figs 3 and 4). In all experimental groups and in all organs, talin-
olol concentrations reached maximum levels 30 min to 1 h after drug administration. A second peak in talinolol 
concentration was observed 2 h after drug administration only in the ileum of fasted male mice. Talinolol concen-
trations were highest in mouse ileum, with liver and plasma levels being 10 and 100 times less respectively. Area 
Under the Curves (AUC) and maximum values (Cmax) of time-concentration profiles were smaller in females than 
in males, irrespective of organ, feeding condition or dosing ZT (Table S4). AUC values were consistently smaller 
at ZT15 compared to ZT3 in all conditions, except in the liver of fasted male mice. Four-way ANOVA testing 
organ, sex, feeding status and ZT of administration revealed statistically significant differences in AUC and Cmax 
values (p < 0.0001) for all factors and interactions.
physiologically-based model as a tool for experimental design. The physiologically-based model 
of talinolol chronoPK was calibrated to both ileum P-gp protein and talinolol PK datasets, so as to analyze P-gp 
activity at whole organism level (Fig. 5A). A set of parameters was estimated for each group, male or female, and 
feeding condition, ad libitum fed or fasting. For fed mice, ileum P-gp circadian periods, amplitudes and phases 
were set to those estimated from protein data (Fig. 1). For fasted mice, circadian periods were set to those found 
for fed animals of the same sex (24 h for females, 12 h for males) and corresponding circadian amplitudes and 
phases were estimated from PK datasets. Circadian phases of renal and intestinal clearance were assigned to occur 
during the nocturnal active phase, i.e. between ZT12 and ZT2438. Amplitudes in fasted mice were assumed to be 
less than those in ad libitum fed animals as fasting decreased P-gp expression circadian amplitudes compared to 
ad libitum feeding39,40. This first parameter estimation procedure failed to predict reliably hepatic P-gp circadian 
activity. Sensitivity analysis on model parameters could not rule out an important contribution of hepatic P-gp 
rhythms to the whole-organism P-gp detoxification function. Hence, we experimentally determined the 24 h 
patterns of P-gp protein level in the liver of ad libitum fed male and female mice (Fig. 5B).
Sex-specific circadian changes in P-gp levels in liver. The expression of liver P-gp protein displayed 
circadian changes in females with a major peak at ZT4 and a secondary peak at ZT20 (Fig. 5B). A predominant 
24 h-rhythm and significant 12 h and 8 h harmonics were identified with cosinor analysis for females (p = 0.024) 
but not for males (p = 0.23). Two-way ANOVA tests statistically validated the effect of ZT (p < 0.0001) and of 
ZT*sex (p < 0.0001), but not that of sex alone (p = 0.53) in these datasets. Twenty-four-hour mean values were 
similar in both sexes (Table S3).
P-gp activity as predicted by physiologically-based analysis of multi-type data. A second param-
eter estimation procedure was run, that now integrated the hepatic P-gp protein data (Fig. 6 and Supplementary 
data). This allowed to compute optimal parameter values and standard deviations for each of the 4 mouse catego-
ries. Both sex and feeding conditions significantly influenced estimated circadian mesors, amplitudes and phases 
of both intestinal and hepatic P-gp activity (two-way ANOVA significant for all P-gp related parameters).
Regarding sex–related differences, the model-estimated mesors of P-gp activity were higher in male compared 
to female ileum and liver, in both feeding conditions. Talinolol passive diffusion rates from the intestinal lumen 
to intestinal cells were also faster in males compared to females (Fig. S3B). Model-estimated circadian amplitudes 
were consistently larger in females as compared to males. Circadian phases also significantly varied by up to 10 h 
with respect to sex.
The model predicted fasting to increase P-gp activity in both liver and ileum in male mice, which was in agree-
ment with prior reports7,8, thus providing a partial model validation. All model-derived circadian amplitudes 
were decreased in fasted mice compared to ad libitum fed animals. No conclusion could be drawn regarding the 
effect of fasting on circadian phases as the estimated parameters presented large standard deviations (Fig. 6C,F).
Sex-, feeding and circadian time-specific talinolol elimination as predicted by physiologically- 
based analysis. The mathematical model was utilized to analyze the circadian changes in talinolol elimina-
tion in the 4 mouse classes (Fig. 7). The model predicted that renal excretion was by far the main route of elimina-
tion with transport rates being 5 orders of magnitude greater compared to intestinal clearance, in good agreement 
with the scientific literature, thus providing once more a partial model validation22. Two-way ANOVA validated 
sex- and feeding-related differences in model-estimated 24 h-mean of renal elimination (sex* feeding p < 0.001). 
Highest renal eliminations were predicted in fasting conditions. Model-estimated amplitudes of renal excretion 
rhythms differed according to sex with slightly smaller values for females compared to males. Regarding intestinal 
elimination, the model-derived 24 h-means significantly differed according to both sex and feeding conditions 
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Figure 2. Sex-specific P-gp expression in the colon mucosa. (A–C) Circadian patterns of Abcb1a (A) and 
Abcb1b (B) mRNA expression, and whole P-gp protein (C). Each data point is the average (±SEM) of 5 animals. 
Solid lines are the best-fit cosinor (Table S2). Regarding mRNAs, no rhythms were demonstrated neither for 
males nor for females (all p values > 0.05). For P-gp protein, no rhythm was found for males (p > 0.05) and a 
12 h-rhythm was found in females (p < 0.001). (D–G) Confocal immunohistochemistry imaging of colon P-gp 
protein expression at ZTs of minimum and maximum values that were in female mice at ZT9 (D) and ZT15 (E), 
and in male mice at ZT9 (F) and ZT15 (G). Pictures represent merged images showing cell nuclei (blue), P-gp 
(green), β-catenin (red) and co-localization of P-gp and β-catenin (yellow). The scale bar represents 20 µm.
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(p < 0.001), and were least in fasted animals, possibly resulting from the reduced gastric motility in the absence of 
food41. No difference was validated for circadian amplitudes according to sex or feeding condition, but acrophases 
varied according to both factors (ANOVA, p < 0.001). Model-estimated renal and intestinal elimination displayed 
relative circadian amplitudes of approximately 50% with circadian phases occurring between ZT14 and ZT20 
consistently with previous results, thus providing a further model validation38,42–44. 
Determinants of intestinal and liver talinolol pK. Sensitivity analysis were performed to determine 
the key model parameters driving talinolol tissue concentrations for all mouse categories (Fig. 5C,D). Talinolol 
concentration in the ileum was mainly determined by 4 quantities: 24 h-mean and phase of renal elimination, 
24 h-mean of ileum P-gp activity and circadian time of administration. On the opposite, talinolol liver concen-
tration was determined by multiple parameters including liver-to-blood transport rate, ileum P-gp 24 h-mean, 
amplitude and phase, and renal elimination 24 h-mean and phase. Altogether, these results confirmed the min-
imal influence of intestinal clearance and highlighted the critical relevance of active intestinal P-gp activity and 
passive renal elimination, and their circadian rhythms for talinolol tissue PK.
Ex-vivo p-gp expression in ileum mucosa. To further investigate the endogenicity of P-gp circadian 
rhythms and their sex-specificity, P-gp expression was quantified ex-vivo in ileum mucosa samples isolated 
from male and female Abcb1a-luc reporter mice because Abcb1a is the closest murine homologue of the human 
ABCB1 gene, which codes for P-gp45 (see Methods, Fig. 8). Significant circadian rhythms were found for both 
sexes with a period of 26 h 35 ± 38 min (SD) for males and 24 h ± 3 min for females (p < 0.001). Maximum 
amplitudes relative to mesor were larger in females as compared to males with mean values (±SD) equal to 
127% ± 6% and 51% ± 12% respectively. Circadian phases (±SD) were located at 19 h 13 ± 3 min for females 
Figure 3. Talinolol ChronoPK in female mice. Concentration-time profiles in ad libitum fed (A–C) or fasted 
(D–F) mice after drug oral administration at ZT3 or ZT15. Each data point represents the mean ± SEM of 4 to 5 
mice. Solid and dashed curves are the model best-fit to data points.
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and at 11 h 32 ± 57 min for males so that their respective values in radians differed by 37% of 2π. The dampening 
parameter was smaller in females (0.0054 ± 0.0004 h−1) as compared to males (0.0096 ± 0.001 h−1). Inter- and 
intra-individual variabilities were slightly larger in males as compared to females although they were remarkably 
low in this experiment (Fig. 8).
Discussion
P-gp can critically affect whole-body PK of many medications including numerous anticancer agents, thus driv-
ing drug tolerability. Hence, predicting P-gp dynamics within individual subjects could allow for dosing sched-
ule personalization in order to minimize side effects. The current investigation revealed that this was indeed a 
multi-factorial challenge, as P-gp expression and activity largely varied according to organ, sex, feeding status 
and circadian time, in an inter-related manner. Hence, quantitative systems pharmacology appeared mandatory 
to jointly address the issue of P-gp substrates dose and timing according to sex and feeding. The data-driven 
mathematical model that was developed successfully recapitulated multi-type experimental datasets and provided 
educated model predictions. The model was further validated through its good agreement with independent data 
reported in scientific literature. Importantly, the analysis of each dataset separately would not have allowed us to 
estimate P-gp activity according to the multiple studied factors.
P-gp mRNA and protein levels were rhythmic in the ileum, which is a major organ for drug absorption. An 
ex-vivo study of organotypic slices demonstrated – for the first time -endogenous circadian rhythms of P-gp pro-
tein expression in ileum mucosa in the absence of external synchronizer or internal time cue. On the opposite, 
P-gp expression did not show major time-dependent variations in the colon. This was in agreement with a recent 
in vitro study in human colorectal Caco-2 cells that concluded that P-gp circadian rhythms played a minor role in 
the chronotoxicity of irinotecan which was mostly driven by the rhythms in drug bioactivation and metabolite 
deactivation16.
Figure 4. Talinolol ChronoPK in male mice. Concentration-time profiles in ad libitum fed (A–C) or fasted 
(D–F) mice after drug oral administration at ZT3 or ZT15. Each data point represents the mean ± SEM of 4 to 5 
mice. Solid and dashed curves are the model best-fit to data points.
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A second peak in talinolol time-concentration profiles was observed 2 hours after drug administration 
in fasted male mice treated at ZT3. This double-peak phenomenon has been found in talinolol PK studies in 
patients46,47. Enterohepatic recirculation is the classical explanation for such double-peak PK but it may not be rel-
evant for talinolol which displays limited reabsorption46,48. A possible explanation rather involves a pre-systemic 
drug processing through talinolol binding to bile acids in the intestinal lumen as demonstrated for pafenolol in 
fasted rats48,49. Indeed, pafenolol formed micellar complexes with bile acids in the proximal small intestine, which 
dissociated in the ileum, thus enabling pafenolol ileum absorption and its translation into the second peak in 
plasma drug concentration. This phenomenon was not present in ad libitum fed animals as food may prevent the 
formation of such complexes49.
Large sex-related differences were observed in intestinal and hepatic P-gp activity 24 h-means, which were 
estimated to be higher in males compared to females. Circadian amplitudes of P-gp mRNA and protein level 
rhythms were consistently higher in females than in males in all organs and in all feeding conditions. The cellular 
basis of the sex-related differences in circadian P-gp protein was further highlighted through continuous biolu-
minescence reporter monitoring and time series analysis of ex vivo ileum mucosa samples from Abcb1a-luc mice. 
Indeed, the endogenous period of the bioluminescent protein was significantly shorter, the relative circadian 
amplitude was larger, and the acrophase occurred later in females as compared to males. Prior studies showed 
significantly larger circadian amplitudes in rest-activity and plasma corticosterone in female, as compared to male 
mice of the same strain and with similar age as those used in the current study26. This was also the case for the 
circadian mRNA expressions of clock genes Rev-erbα, Per2, and Bmal1 in the liver of female as compared to male 
mice27. Further, recent preclinical and clinical investigations showed higher circadian amplitudes in females com-
pared to males in the chronotoxicity of the anticancer drug irinotecan, which is a P-gp substrate27,50. Differences 
in feeding patterns between males and females could also play a role in the sex-specific variations demonstrated 
here for P-gp expression and activity since food intake was reported to be larger in females as compared to male 
C57Bl/6 mice51. The fasted mice receiving talinolol at ZT3 were fasted from ZT15 to ZT3 and remained fasted for 
up to 8 h, for the duration of talinolol PK experiments, i.e. until ZT 11. The fasted mice receiving talinolol at ZT15 
were fasted from ZT3 to ZT15, then for up to 8 h until ZT23. Hence, fasting time was the same in both subgroups, 
but the fasting circadian window was different, which could represent a limitation of our study.
An important motivation for this work was the design of a model of irinotecan chronoPK-PD for the person-
alization of the drug chronotherapy, including sexual dimorphism in toxic response to treatments4. The clinical 
relevance of sex-related toxicities has been demonstrated for the hematologic or mucosal toxicities of anticancer 
drugs 5-fluorouracil, oxaliplatin, or irinotecan. In these large studies, women displayed higher toxicity rates by 
up to 15% as compared to men9,52–54. Consistently with these findings, a data mining analysis of global liver 
safety reports was conducted for 375 drugs associated with hepatotoxicity, from WHO VigiBaseTM55. A higher 
overall liver event reporting for women and a higher reporting of acute liver failure for younger women were 
identified56. Forty-one drugs with female-biased reported frequencies were associated with a higher prevalence of 
reactive metabolite formation and mitochondrial liability, and higher ABCB11 and ABCC2 transporter inhibition 
Figure 5. Physiologically-based model of talinolol PK. (A) Physiologically-based model of talinolol chronoPK, 
(B) P-gp protein expression in the liver of female (red) and male (blue) mice and best-fit cosinor (C–D) Global 
sensitivity of model parameters to talinolol AUC0–8h in the liver (C) and the ileum (D).
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Figure 6. Ileum and hepatic P-gp activity according to sex, feeding and circadian timing. Mesors, amplitudes 
and phases (averages ± SD) of P-gp activity estimates from physiologically-based analysis of P-gp protein and 
talinolol PK data are shown in fed and fasted male mice (dark and light blue respectively) and in fed and fasted 
females (dark and light pink respectively). Circadian amplitudes and phases of P-gp activities in fed animals 
were directly derived from the cosinor analysis of protein data (panels B, C, E and F). P-gp hepatic activity in ad 
libitum fed male mice did not display significant circadian rhythms so that the amplitude was equal to 0 and no 
phase could be computed.
Figure 7. Talinolol renal and intestinal elimination according to sex, feeding and circadian timing. Mesors 
amplitudes and phases (averages ± SD) of P-gp activity estimates from physiologically-based analysis of P-gp 
protein and talinolol PK data are shown in fed and fasted male mice (dark and light blue respectively) and in fed 
and fasted females (dark and light pink respectively).
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potential. Moreover, our studies further highlighted that the tolerability of irinotecan, like that of oxaliplatin, 
largely varied according to sex and circadian timing in mice and/or in humans4,57.
A mathematical model of irinotecan chronoPK-PD has been developed but model calibration was not possible 
due to the large number of parameters to be estimated simultaneously58. Importantly, the present study has provided 
estimates for the circadian amplitudes and phases of P-gp hepatic and ileum circadian activity in B6D2F1 male and 
female mice, either ad libitum fed or fasted. Those parameter values can be directly incorporated into the irinote-
can PK-PD model. This is a critical step towards the complete calibration of the model, that will then be used for 
optimizing irinotecan chronotherapy for each mouse category. The model will also assist in the identification of key 
circadian determinants of irinotecan chronotoxicity. Interestingly, the circadian rhythms in P-gp activity that were 
identified in this study are likely to be mainly driven by the amount of active P-gp molecules within the cell mem-
brane and thus to be drug-independent. Hence, the estimated circadian amplitudes and phases of P-gp hepatic and 
intestinal activity can be incorporated into PK models of any P-gp substrate studied in B6D2F1 mice. Hence, this 
study has provided all the mathematical components- equations and parameter estimates- needed to extend classical 
physiologically-based PK models to incorporate sex-specific circadian rhythms.
Our study lays the grounds for further human application. Such PK-PD model holds the potential to be 
scaled for humans to predict optimal drug dose and timing in individual patients4. From a general standpoint, 
physiologically-based modelling allows for multiscale chronoPK-PD approaches aiming to design human mod-
els based on both preclinical and clinical data. Mouse studies serve as a basis to design the drug-specific struc-
ture of the whole-body PK-PD model, which incorporates the drug pharmacology in each considered organ. 
Next, a model for an average patient can be obtained by keeping the structure of the mouse model and resizing 
the parameters for humans using physiological literature information combined to clinical datasets in patient 
populations. The generic model can then be informed with patient-specific features such as the patient’s sex, 
chronotype or P-gp polymorphisms, to ultimately compute personalized dose and administration schedules. This 
model translation from preclinical studies to humans holds great promises towards personalized and precision 
medicine4.
Methods
Animals and synchronization. Male and female B6D2F1 mice (5 to 7 weeks of age, Janvier, Le Genest 
St Isle, France) or heterozygous B6;129S1-Abcb1atm1.1Kane mice45 (crossing of heterozygous C57B/L6 male and 
homozygous B129 mice, referred to as Abcb1a-luc mice thoughout the text, 8–10 weeks of age, a kind gift from 
Susan Kane, Beckman Research Institute, City of Hope, Duarte, CA 91010-3000, USA) were held in temperature 
controlled (23 ± 1 °C), ventilated (100 ± 10 l/min) and light tight boxes with 12 h of light (L) alternating with 12 h 
of darkness (D) (LD12:12) and ad libitum access to food and water. Animals were housed in the controlled room 
for three weeks before starting the experiments. Dim red light (7 lux) was used for manipulations during the dark 
phase. Time of day is referred as Zeitgeber Time (ZT) with ZT0 corresponding to light onset. Whenever mice 
were fasted, food access was withdrawn 12 h before the first experimental intervention. All experimental proto-
cols were conducted following the guidelines for animal experimental procedures issued by the French Ethical 
Figure 8. Sex-specific endogenous circadian rhythms in Abcb1a reporter expression in ex-vivo ileum mucosa 
samples. Detrended bioluminescence timeseries recorded from 3 different female (A) and male (B) mice. 
Duplicates from the same animal are represented in the same color. Circadian rhythms were statistically 
validated for all individual timeseries.
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Committee, decree 87–848 and the European Communities Council Directive of 24/11/1986 (86/609/EEC). The 
experimental protocols were approved by the experimental animal sub-committee of the Andre Lwoff Institute 
(Villejuif, France) or by the Home Office (UK, Project Licence 7008536).
Compounds and reagents. Talinolol and escitalopram were generously given by Arzneimittelwerk 
Dresden (AWD Pharma, Radebeul, Germany) and Neutec Pharmaceutical Co. (Istanbul, Turkey) respectively. 
Buffer salts, solvents and reagents were purchased from E. Merck (Darmstadt, Germany) unless stated otherwise.
mRNA expression studies. Abcb1a/b mRNA expression were determined with RT-qPCR25. Samples were 
immediately frozen in liquid nitrogen, then stored at −80 °C. Total RNA was extracted from frozen specimens 
by liquid-liquid extraction. Each sample was first homogenized with 2 mL lysis buffer GIT (guanosine isothiocy-
anate), then sodium citrate and N-lauryl sarcosine 10%, 2-mercaptoethanol were added. The lysate was recovered 
in a tube for RNA59. Next, phenol and chloroform isoamyl (24:1, v/v) were added. After agitation, the samples 
were incubated for 15 min on ice and then centrifuged (20 min, 9660 g at 4 °C). The aqueous phase was then 
recovered. One volume of isopropanol was added, and the mixture was obtained through iterative reversals of 
the solution. Precipitated mRNAs were kept overnight at −80 °C. On the next day, samples were centrifuged 
(30 min, 9660 × g, at 4 °C) and supernatants were removed. The pellets were rinsed with ethanol 70% (500 µl), 
then centrifuged (20 min, 9660 × g at 4 °C). The supernatants were discarded, and pellets dried for 10 min on ice, 
then re-suspended in RNA-free water. RNA-free samples were analyzed by formaldehyde gel electrophoresis, 
and integrity was confirmed by visualization of 18S and 28S rRNA bands. The RNAs obtained were quantified by 
spectrometry (Biophotometer Plus, Eppendorf, France) and stored −80 °C.
Reverse transcription involved a denaturating step of RNA, followed by the retro-transcription step (RT 
Invitrogen, Cergy-Pontoise, France). The thermocycler was used for all stages of heating and cooling. For each 
sample, a solution containing 5 µg of total RNA and 100 ng of random primers (hexamers solution at 100 ng/µl) 
was prepared. It was then heated in the thermocycler at 65 °C for 5 min (denaturation step), then it was cooled 
at 4 °C for 5 min. Along with the denaturing step, the solution required for the retro-transcription was prepared. 
It contained desoxynucleoside triphosphates (dATP, dCTP, dTTP and dGTP) (10 mM), a buffer containing the 
enzyme cofactors essential for enzyme function (250 mM Tris-HCl, 375 mM KCl, 15 mM MgCl2), dithiothreitol 
(0.1 mM solution), and reverse transcriptase (SuperScript II Reverse Transcriptase, Invitrogen, Cergy-Pontoise, 
France). For the reverse transcription step, samples were incubated for 50 min at 42 °C, and then for 15 min at 
75 °C for enzyme denaturation. Next, samples were diluted to the 10th and the PCR was performed using a Light 
Cycler 3 (Roche Applied Science, Meylan France) with SYBR green I dye detection. A reaction mixture (Faststart 
DNA SYBR Green I; Roche Diagnostics, Meylan France) was supplemented with cDNA and primers (0.5 µM). A 
standard curve was generated to compute relative mRNA abundance. mRNA expression levels were normalized 
to the amount of the constitutively and non-rhythmically expressed 36B4 (acidic ribosomal phosphoprotein)25.
P-gp protein expression in ileum and colon mucosa. Ileum and colon mucosa samples were analysed 
as described in25. Briefly, samples were fixed in buffered formalin solution (4%), kept at room temperature for 24 h, 
dehydrated in ethanol, cleared in Bioclear (Bioptica, Milan, Italy) and embedded in paraffin. Five- µm sections 
were transferred to positively charged slides which were incubated overnight at 37 °C and immersed in xylene. 
Tissue sections were rehydrated (graded alcohol series 100%, 96% and 80% for 5 min each and rinse in water) and 
stained with haematoxylineosin. Immunohistochemistry (IHC) analysis was performed as described in25 using a 
mouse anti-mouse P-gp antibody (Covance, Princeton, NJ, USA; diluted 1/20) and a rabbit anti-mouse β-catenin 
antibody (Neomarkers, Fremont, CA, USA; diluted 1/50). Three images were collected for each tissue section 
corresponding to β-catenin positive areas as this latter protein is co-localized with P-gp at the intestinal mucosa. 
Image analysis was performed as described in25.
talinolol chronopK study. Talinolol was suspended in methylcellulose (0.5%) and administered via oral 
gavage (100 mg/kg). Controls received only vehicle, i.e. 0.5% methylcellulose solution. A single dose of talinolol 
was administered to 60 male and 60 female mice at ZT3 or ZT15. Those times of administration were chosen 
according to previous results in male mice18,20 or rats22 and are associated to low (ZT3) and high (ZT15) intestinal 
P-gp activity. The study involved 4 or 5 mice of each sex sacrificed 30 min, 1, 2, 4, 6 and 8 h after talinolol admin-
istration. Mice were sacrificed and blood samples (~1 mL each) were drawn on heparin from the retro-orbital 
sinus. Blood samples were immediately centrifuged at 12,000 rpm for 10 min at 4 °C and plasma was separated. 
Liver and ileum mucosa were sampled immediately following sacrifice. Ileum samples were cut longitudinally, 
washed with isotonic saline solution and dried gently. The mucosa layer was scraped with a scalpel. All samples 
were kept at −25 °C until analyses.
Determination of talinolol in plasma. The analysis of plasma talinolol was carried out with High 
Performance Liquid Chromatography (HPLC), using Waters 2695 pump, autosampler, column heater-sample 
cooler (Waters, Milford MA, USA) and Waters 2487 UV/VIS detector (Waters, Milford MA, USA)22. Talinolol 
was extracted from plasma by hydrophilic-lipophilic balance type solid phase extraction cartridges (Oasis® SPE 
cartridges 1 cc/30 mg; Waters, Milford MA, USA) and reversed phase Phenomenex C18 column (250 × 4,6 mm; 
5 µm, Waters, Milford MA, USA) connected with a universal Phenomenex C18 precolumn (2,1 × 3,9 mm; 5 µm, 
Varian-USA). The extraction was carried out using a dedicated sample preparation product (VacElut, Varian, Palo 
Alto CA, USA) and a vacuum pump (KNF, Freiburg, Germany). Firstly, cartridges were conditioned with 1 mL 
HPLC grade methanol and 1 mL HPLC grade water (Millipore, Milford MA, USA), then 0.25 mL plasma were 
passed through the cartridges. Cartridges were rinsed with 1 mL HPLC grade water and water:methanol (95:5, 
v/v) for unretained matrix, then talinolol was collected in clean tubes by eluting with 0.5 mL methanol (20 µl). A 
mixture of 0.05 M phosphate buffer/acetonitrile (73:27, v/v; pH: 4) was used as a mobile phase for HPLC. Flow 
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rate was 1 mL/min, the column temperature was adjusted to 40 °C and wavelength eluent monitoring was 242 nm. 
Retention time of talinolol was 9.5 min and the limit of determination was 50 ng/mL. Intra-day reproducibility 
was 6.1% for 1 µg/mL and 4.5% for 0.25 µg/mL. Inter-day reproducibility was 6.5% and 2.9% for 1 and 0.25 µg/mL, 
respectively.
Determination of talinolol in liver and ileum mucosa. Liver and ileum mucosa samples were homog-
enized using 0.9% NaCl in water (1:5–1:10 ratio w:v) with UltraTurrax (Germany) 2 min for liver, 30 sec for 
ileum mucosa, and vortexed for 1 min for both tissues. Talinolol was determined in homogenized tissue ali-
quots (200 µl) using the same HPLC-UV/VIS detector60. Talinolol was extracted by liquid-liquid extraction using 
2 mL ter-methyl butyl ether, following addition of internal standard (IS), 10 µl (4,5 µg/mL) escitalopram (Neutec 
Pharmaceutical Co., Istanbul, Turkey) and 200 μl of 0.5 M NaOH. After addition of all reagents, the mixture was 
vortexed and, centrifuged at 2500 g for 2 min. The organic layer was collected in a clean tube and evaporated in 
a block heater at 55 °C (Stuart, UK). The samples were reconstituted in 200 µL of mobile phase and analyzed by 
HPLC on a Phenomenex column (250 × 4 mm; 5 µm, Varian, USA) connected with a universal Phenomenex 
C18 precolumn (4 × 4 mm; 5 µm, Varian). Mobile phase contained 0.05 M phosphate buffer/acetonitrile (66:34, 
v/v; pH: 3.1) at a flow rate of 1 mL/min with column temperature set at 35 °C, the injection volume was 45 μL 
and wavelength for eluate monitoring was 245 nm. Triethylamine was used as peak modifier (0.6 mL per liter). 
Retention time of talinolol was 4.4 min and retention time of IS escitalopram was 6.2 min. Variability of the assay 
ranged from 2 to 10%, and the limit of determination was 50 ng/mL.
Liver P-gp protein expression. Forty-eight male and 48 female B6D2F1 mice were randomized into 8 
groups of 6 mice per sex each and entrained to LD12:12 cycles for two weeks. Mouse liver was sampled from 
separate groups at ZT1, 4, 7, 10, 13, 16, 19, and 22. After flushing the liver with PBS, it was extracted, weighed 
and immediately frozen and stored till analysis at −80 °C. Liver tissue was homogenized in 1 ml PBS/g of liver on 
ice by fast rotating homogenizer (T10 basic Ultra-Turrax Homogenizer, IKA, Germany), then subjected to three 
freeze-thaw cycles. Protein supernatant was collected after centrifugation (15 min, 2500 g, 4 °C). Total protein 
was quantified using Bradford protein assay (AppliChem GmbH, Darmstadt, Germany) prior to P-gp determi-
nation. P-gp protein content was quantified using ELISA according to the manufacturer’s instructions (Mouse 
Permeability Glycoprotein Elisa kit, Blue Gene Biotech, Shanghai, China).
p-gp protein expression in ex-vivo ileum mucosa. Six Abcb1a-luc mice (3 males and 3 females) aged 
12 weeks were entrained to LD12:12 cycles for 2 weeks prior to experiments45. On the day of the experiment, 
the mice were euthanized by cervical dislocation at ZT3 and ileum mucosa was sampled and stored in ice cold 
HBSS (Sigma, Dorset, UK). The isolated ileum mucosa was cleaned with HBSS buffer and cut in a longitudinal 
section to expose the inner lumen. The ileum mucosa from each mouse was divided into two samples to serve as 
intrasubject replicates. The slices were put on 30 mm polytetrafluoroethylene inserts with a pore size of 0.4 µm. 
in 35 mm tissue culture dishes (Thermo, Cambridge, UK) and 1.2 mL culture medium (phenol-free DMEM, 10% 
FBS, 1% Pen/Step, 10 mM HEPES) with 20 µM luciferin. The dishes were sealed with silicon grease and put into a 
Lumicycle (Actimetrics, Illinois, USA) at constant temperature (37 °C) to measure the bioluminescence as photon 
counts per min every 10 min for up to 6 days.
statistical analysis. Variance arising from organ, sex, feeding condition and circadian timing was tested 
though multi-factor ANOVA. The statistical significance of a cosine waveform was determined with cosinor 
analysis testing for the main period of 24 h and the two first harmonics at 12 h and 8 h61. Time series involved one 
datapoint every 3 h for 24 h which theoretically allows for the determination of oscillations with periods above 6 h 
according to Nyquist theorem62. The cosinor method computes the mesor (rhythm-adjusted mean), and, for each 
harmonic, the double amplitude (difference between minimum and maximum of fitted cosine function), and the 
phase (time of maximum in best-fitting cosine function). The Area Under the Curve (AUC) over the first 8 h of 
drug exposure and the maximum concentration Cmax of talinolol PK curves were computed from experimental 
data as follows. For each mouse dataset, talinolol time-concentration profiles were generated by randomly com-
bining individual mouse PK measurements for each time point. This was done for all possible combinations and 
yields approximately 5000 curves from which Cmax and AUC values were computed. Means and standard devi-
ations were then inferred for each condition. Regarding the analysis of ex-vivo ileum mucosa bioluminescence, a 
linear trend was removed from time series, which were then normalized to obtain a mean value equal to 1. Then, 
a damped cosine was fitted to detrended normalized data, using a least-square method, to compute the period, 
phase, maximum amplitude and dampening parameter63. Significance for all tests were set to p < 0.05. SPSS v.16 
(IBM, Paris, France) or Matlab (Mathworks, USA) were utilized for statistical tests.
Model parameter estimation and sensitivity analysis. Parameter estimation consisted in a weighted 
least-square approach using the Covariance Matrix Evolutionary Strategy (CMAES) algorithm for the minimiza-
tion task16,63. Averaged data were first fitted by iteratively running the estimation procedure and updating initial 
conditions with the current best-fit parameters until reaching convergence. Next, data variability was integrated 
by using Monte Carlo simulations. Briefly, virtual datasets of talinolol PK in the ileum, liver and plasma were 
composed by randomly picking an individual mouse for each time point. Parameters were then estimated for 
each virtual dataset and averages and standard deviations were computed. Two hundred datasets were necessary 
to insure convergence for all parameters. For sensitivity analysis, all parameters’ lower and upper bounds were set 
to 10-fold lesser and greater than their estimated values on averaged data. Forty-eight thousand parameter sets 
were generated from cross-sampling by Saltelli’s extension of Sobol’s method using the MOEA (Multi-Objective 
Evolutionary Algorithms) framework (version 2.0). Parameters’ total-order sensitivity indices and their standard 
deviations were computed using the Sobol analysis of the MOEA framework.
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